Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate

被引:22
作者
Cwik, MJ [1 ]
Liang, MZ [1 ]
Deyo, K [1 ]
Andrews, C [1 ]
Fischer, J [1 ]
机构
[1] WESTERN CHINA UNIV MED SCI,CHENGDU,SICHUAN,PEOPLES R CHINA
来源
JOURNAL OF CHROMATOGRAPHY B | 1997年 / 693卷 / 02期
关键词
phenytoin; fosphenytoin;
D O I
10.1016/S0378-4347(97)00057-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of phenytoin and fosphenytoin, a prodrug for phenytoin, in human plasma and plasma ultrafiltrate is described. For plasma, the method involves simple extraction of drugs with diethyl ether and evaporation of solvent, followed by injection of the reconstituted sample onto a reversed-phase C-18 column. Plasma ultrafiltrate is injected directly into the HPLC column. Compounds are eluted using an ion-pair mobile phase containing 20% acetonitrile. The eluent is monitored by UV absorbance at 210 nm. The fosphenytoin standard curves are linear in the concentration range 0.4 to 400 mu g/ml for plasma and 0.03 to 80 mu g/ml for ultrafiltrate. Phenytoin standard curves are linear from 0.08 to 40 mu g/ml for plasma and from 0.02 to 5.0 mu g/ml for ultrafiltrate. No interferences with the assay procedure were found in drug-free blank plasma or plasma ultrafiltrate. Relative standard deviation for replicate plasma or ultrafiltrate samples was less than 5% at concentrations above the limit of quantitation for both within- and between-run calculations.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 8 条
[1]  
BOUCHER B, 1979, AJ PHARM SCI, V78, P929
[2]  
FISCHER J, 1995, NEUROLOGY, V45, pA202
[3]   SAFETY, TOLERANCE AND PHARMACOKINETICS OF INTRAVENOUS DOSES OF THE PHOSPHATE ESTER OF 3-HYDROXYMETHYL-5,5-DIPHENYLHYDANTOIN - A NEW PRODRUG OF PHENYTOIN [J].
GERBER, N ;
MAYS, DC ;
DONN, KH ;
LADDU, A ;
GUTHRIE, RM ;
TURLAPATY, P ;
QUON, CY ;
RIVENBURG, WK .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (11) :1023-1032
[4]   DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC (HPLC) METHOD FOR THE DETERMINATION OF PHENYTOIN PRODRUG (FOSPHENYTOIN) IN SOLUTIONS, PARENTERAL FORMULATIONS, AND ACTIVE-DRUG SUBSTANCE [J].
HERBRANSON, DE ;
KRISSDANZIGER, P .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1993, 16 (05) :1143-1161
[5]   ABSOLUTE BIOAVAILABILITY OF PHENYTOIN AFTER 3-PHOSPHORYLOXYMETHYL PHENYTOIN DISODIUM (ACC-9653) ADMINISTRATION TO HUMANS [J].
JAMERSON, BD ;
DONN, KH ;
DUKES, GE ;
MESSENHEIMER, JA ;
BROUWER, KLR ;
POWELL, JR .
EPILEPSIA, 1990, 31 (05) :592-597
[6]  
Kugler Alan R., 1994, Pharmaceutical Research (New York), V11, pS102
[7]   PHARMACOKINETICS AND SAFETY OF A PHENYTOIN PRODRUG GIVEN IV OR IM IN PATIENTS [J].
LEPPIK, IE ;
BOUCHER, BA ;
WILDER, BJ ;
MURTHY, VS ;
WATRIDGE, C ;
GRAVES, NM ;
RANGEL, RJ ;
RASK, CA ;
TURLAPATY, P .
NEUROLOGY, 1990, 40 (03) :456-460
[8]   CLINICAL-RESPONSE IN EPILEPSY IN RELATION TO TOTAL AND FREE SERUM LEVELS OF PHENYTOIN [J].
PETERSON, GM ;
KHOO, BHC ;
VONWITT, RJ .
THERAPEUTIC DRUG MONITORING, 1991, 13 (05) :415-419